-+ 0.00%
-+ 0.00%
-+ 0.00%

Esperion reports Phase 2 pediatric study shows bempedoic acid lowers LDL-C in HeFH

PUBT·05/13/2026 12:03:28
Listen to the news
Esperion reports Phase 2 pediatric study shows bempedoic acid lowers LDL-C in HeFH
  • Esperion flagged new analyses on bempedoic acid, with results scheduled for presentation May 24-27 at European Atherosclerosis Society Congress 2026 in Athens.
  • Phase 2 pediatric study in children with heterozygous familial hypercholesterolemia showed LDL-C reductions consistent with adult experience, supporting plans to move into Phase 3 development for pediatric familial hypercholesterolemia.
  • Separate analysis from CLEAR Outcomes identified patient characteristics linked to more pronounced LDL-C lowering in statin-intolerant adults, aiming to guide use in clinical practice.
  • Company also slated encore presentations from CLEAR Outcomes analyses on venous thromboembolism risk, stroke incidence, and outcomes without background lipid-lowering therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130800PRIMZONEFULLFEED9718381) on May 13, 2026, and is solely responsible for the information contained therein.